-
Signature
-
/s/ Christiana Stevenson, Attorney-in-Fact
-
Issuer symbol
-
VRTX
-
Transactions as of
-
24 Feb 2026
-
Net transactions value
-
-$2,817,866
-
Form type
-
4
-
Filing time
-
26 Feb 2026, 18:48:22 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| McKechnie Duncan |
EVP, Chief Commercial Officer |
C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON |
/s/ Christiana Stevenson, Attorney-in-Fact |
26 Feb 2026 |
0002062139 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
VRTX |
Common Stock |
Tax liability |
$423,501 |
-873 |
-3.7% |
$485.11 |
22,469 |
24 Feb 2026 |
Direct |
|
| transaction |
VRTX |
Common Stock |
Sale |
$1,215,875 |
-2,500 |
-11% |
$486.35 |
19,969 |
25 Feb 2026 |
Direct |
F1 |
| transaction |
VRTX |
Common Stock |
Sale |
$1,178,490 |
-2,410 |
-12% |
$489.00 |
17,559 |
25 Feb 2026 |
Direct |
F1 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: